Pacific Biosciences of California, Inc. (PACB) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Pacific Biosciences of California, Inc. (PACB) Healthcare & Pipeline Overview

Pacific Biosciences (PacBio) specializes in long-read sequencing technology, offering solutions for complex genetic analysis. Their SMRT technology caters to research institutions, commercial labs, and pharmaceutical companies, providing insights into genome structure and function. With a focus on accuracy and comprehensive data, PacBio addresses critical needs in genomics.

What Is the Investment Thesis for PACB?

Pacific Biosciences presents a compelling, albeit high-risk, investment opportunity within the genomics sector. The company's SMRT sequencing technology offers advantages in long-read sequencing, crucial for resolving complex genomic structures. While the company currently operates with a negative profit margin of -80.3%, the potential for revenue growth through increased adoption of its PacBio Systems and consumables is significant. Key to the investment thesis is the expansion of PacBio's market share in clinical and applied markets, driven by ongoing technological advancements and strategic partnerships. Upcoming catalysts include new product launches and expanded collaborations, which could drive revenue growth and improve profitability. However, investors should be aware of the high beta of 2.33, indicating significant volatility, and the competitive landscape, which includes established players with substantial resources.

Based on FMP financials and quantitative analysis

PACB Key Highlights

Market capitalization of $399M reflects investor valuation of PacBio's future growth potential in the genomics market.

• Gross margin of 37.1% indicates the profitability of PacBio's sequencing products and services before operating expenses.
• Negative profit margin of -80.3% highlights the company's current focus on growth and investment in R&D, impacting near-term profitability.
• Beta of 2.33 suggests that PACB's stock price is more volatile than the overall market, reflecting the high-growth, high-risk nature of the genomics sector.
• No dividend yield reflects PacBio's strategy of reinvesting earnings to fuel growth and innovation in its sequencing technology.

Who Are PACB's Competitors?

PACB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are PACB's Key Strengths?

Proprietary SMRT technology enables long-read sequencing.

• Strong focus on accuracy and comprehensive data.
• Established presence in research and academic markets.
• Growing installed base of PacBio Systems.

What Are PACB's Weaknesses?

Negative profit margin and reliance on external funding.

• High beta indicates significant stock price volatility.
• Limited market share compared to larger competitors.
• High cost per base compared to short-read sequencing.

What Could Drive PACB Stock Higher?

Launch of new SMRT cell technology with improved throughput and accuracy.

• Expansion of strategic partnerships with pharmaceutical companies for drug discovery applications.
• Increasing adoption of PacBio's sequencing solutions in clinical research and diagnostics.
• Publication of key research studies highlighting the benefits of long-read sequencing in complex genomic analysis.

What Are the Key Risks for PACB?

Financial-distress signal — its Altman Z-Score of -4.73 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Intense competition from established sequencing companies with greater resources.
• Technological advancements by competitors could render PacBio's technology obsolete.
• Regulatory hurdles and reimbursement challenges in clinical diagnostics.
• Economic downturns could impact research funding and capital spending, reducing demand for sequencing services.
• Reliance on key suppliers for critical components of sequencing systems.

What Are the Growth Opportunities for PACB?

• Expansion in Clinical Diagnostics: PacBio has a significant growth opportunity in expanding its presence in clinical diagnostics. The increasing adoption of genomic sequencing in healthcare, driven by personalized medicine, creates a demand for accurate and comprehensive sequencing solutions. PacBio's long-read sequencing technology is well-suited for identifying structural variations and complex genomic rearrangements relevant to disease diagnosis and prognosis. This market is projected to grow significantly, offering PacBio the potential to increase its revenue through partnerships with clinical laboratories and the development of diagnostic assays.
• Penetration of the Agricultural Biotechnology Market: The agricultural biotechnology sector represents another substantial growth opportunity for PacBio. Long-read sequencing is valuable for genome assembly and improvement in crops and livestock. PacBio's technology can aid in identifying genes associated with desirable traits, accelerating breeding programs, and enhancing crop yields. As the demand for sustainable agriculture and improved food production increases, PacBio can capitalize on this trend by offering sequencing solutions to agricultural companies and research institutions.
• Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with pharmaceutical companies, research institutions, and other industry players is crucial for PacBio's growth. These collaborations can facilitate the development of new applications for PacBio's technology, expand its market reach, and drive revenue growth. By partnering with companies specializing in specific areas of genomics, PacBio can leverage their expertise and resources to accelerate the adoption of its sequencing solutions in diverse markets. Ongoing collaborations, such as the agreement with Invitae Corporation, are vital for continued expansion.
• Technological Advancements and Product Development: Continuous innovation and product development are essential for PacBio to maintain its competitive edge. Investing in research and development to improve the accuracy, speed, and cost-effectiveness of its sequencing technology will attract new customers and expand its market share. The development of new SMRT cells, reagent kits, and software tools will enhance the capabilities of PacBio's systems and enable new applications in genomics research and clinical diagnostics. Ongoing advancements in long-read sequencing will drive adoption and solidify PacBio's position in the market.
• Geographic Expansion: Expanding its geographic presence, particularly in Asia and emerging markets, represents a significant growth opportunity for PacBio. These regions are experiencing rapid growth in genomics research and healthcare, creating a demand for advanced sequencing technologies. By establishing a stronger presence in these markets through direct sales, distribution partnerships, and strategic collaborations, PacBio can tap into new customer segments and increase its revenue. Tailoring its products and services to meet the specific needs of these markets will be crucial for success.

What Are PACB's Competitive Advantages?

• Proprietary SMRT (Single Molecule, Real-Time) sequencing technology offers unique advantages in long-read sequencing.
• Strong intellectual property portfolio protecting its sequencing technologies and applications.
• Established reputation for accuracy and comprehensive data in complex genomic analysis.
• Growing installed base of PacBio Systems creating recurring revenue from consumables and service contracts.

What Does PACB Do?

Pacific Biosciences of California, Inc., founded in 2000 and headquartered in Menlo Park, California, is a leader in developing and manufacturing advanced DNA sequencing systems. Originally named Nanofluidics, Inc., the company rebranded as Pacific Biosciences in 2005, marking a shift towards its focus on Single Molecule, Real-Time (SMRT) sequencing technology. PacBio's core offering revolves around its PacBio Systems, which facilitate, monitor, and analyze biochemical sequencing reactions. These systems are complemented by consumable products, including SMRT cells and reagent kits tailored for specific workflows, such as template preparation kits for converting DNA into SMRTbell double-stranded DNA libraries. These libraries utilize molecular biology reagents like ligase, buffers, and exonucleases. Additionally, PacBio provides binding kits with modified DNA polymerase for attaching SMRTbell libraries to the polymerase, and sequencing kits containing reagents for real-time sequencing. PacBio serves a diverse clientele, including research institutions, commercial laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, academic institutions, pharmaceutical companies, and agricultural companies. The company markets its products through a direct sales force in North America and Europe, and via distribution partners across Asia, Europe, the Middle East, Africa, and Latin America. PacBio also has a development and commercialization agreement with Invitae Corporation, further expanding its market reach and application of its sequencing technology.

What Products and Services Does PACB Offer?

• Designs and manufactures DNA sequencing systems.
• Develops Single Molecule, Real-Time (SMRT) technology.
• Provides PacBio Systems for biochemical sequencing reactions.
• Offers consumable products like SMRT cells and reagent kits.
• Creates template preparation kits for DNA conversion.
• Supplies binding kits with modified DNA polymerase.
• Markets products through direct sales and distribution partners.

How Does PACB Make Money?

• Sells PacBio Systems, which are the core sequencing platforms.
• Generates revenue from consumable products, including SMRT cells and reagent kits, required for sequencing runs.
• Offers service and support contracts for its installed base of sequencing systems.
• Forms strategic partnerships and collaborations to expand market reach and develop new applications.

What Industry Does PACB Operate In?

Pacific Biosciences operates within the rapidly evolving genomics industry, driven by advancements in DNA sequencing technologies and increasing demand for personalized medicine. The market is characterized by intense competition among companies offering various sequencing platforms, including short-read and long-read technologies. PacBio's long-read SMRT sequencing provides unique advantages in resolving complex genomic regions, positioning it as a key player in structural variation analysis and de novo genome assembly. The industry is experiencing growth driven by applications in drug discovery, diagnostics, and agricultural biotechnology. PacBio competes with established players like Illumina and emerging companies offering alternative sequencing solutions.

Who Are PACB's Key Customers?

• Research institutions conducting genomic studies.
• Commercial laboratories offering sequencing services.
• Genome centers focused on large-scale sequencing projects.
• Pharmaceutical companies involved in drug discovery and development.
• Agricultural companies seeking to improve crops and livestock.

Company Profile

Pacific Biosciences of California, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Menlo Park, US. The company is led by CEO Mark Van Oene. PACB has traded publicly since 2010.

Key Financial Metrics

Return on assets is -16.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -26.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -29.2%, the inverse of the P/E and a quick read on earnings relative to price.

PACB Valuation & Market Position

With a $399M market cap, Pacific Biosciences of California, Inc. sits in the small-cap segment of the market. Analyst price targets span from $1.00 to $1.35, with a consensus of $1.18. At the current price of $1.28, that implies roughly 8% downside from the consensus target. Relative to its peer group, PACB's quantitative score of 15/100 is below the peer average of 74/100.

Quarterly Financial Performance: Pacific Biosciences of California, Inc.

Revenue for Pacific Biosciences of California, Inc. came in at $39.0M during Q2 FY2026, a 4.9% improvement versus the preceding quarter. The company recorded a net loss of $44.7M, with diluted EPS of $-0.14. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, PACB averaged $-0.11 in diluted EPS.

Pacific Biosciences of California, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.73 places it in the distress zone, a signal of elevated financial risk.

Pacific Biosciences of California, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 61.9% below estimates on average.

Over the past six months, Pacific Biosciences of California, Inc. insiders filed 14 SEC Form 4 transactions — 2 sales and 12 purchases. On net that is roughly 4.1M shares acquired (about $4.8M) — insiders putting money in tends to read as conviction.

PACB Financials

PACB Latest News

PACB Analyst Consensus

PACB MoonshotScore

PACB Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources